Status:
RECRUITING
Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
Lead Sponsor:
Deciphera Pharmaceuticals, LLC
Conditions:
Healthy Participants
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using r...
Eligibility Criteria
Inclusion
- Participants are in good general health, as required by the protocol and as determined by Principal Investigator.
- Body mass index (BMI) from 18 to 32 kilogram per square meter (kg/m\^2).
- Adequate organ function and blood and urine tests, as required by the protocol and as determined by Principal Investigator.
Exclusion
- History or presence of clinically significant diseases of the neurological, dermatological, renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems or history or presence of clinically significant psychiatric, immunological, endocrine, or metabolic disease as determined by Principal Investigator.
- Unwilling or unable to comply with the requirements of the protocol.
- Determined by Principal Investigator to be unsuitable to participate in the study for any other reason.
Key Trial Info
Start Date :
October 31 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07158398
Start Date
October 31 2025
End Date
June 1 2026
Last Update
November 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Vince Clinical Research
Overland Park, Kansas, United States, 66212